Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of first-line antihypertensive combination regimens in high-risk Tibetan patients with hypertension
ChiCTR-IPR-17012048Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of olmesartan, amlodipine and hydrochlorothiazide in hypertension (HTN) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Cardiovascular morbidity. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
olmesartanamlodipinehydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR-IPR-17012048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012048.